Posted On: 09/29/2014 12:28:35 PM
Post# of 30066
LP002 LymPro Data will mark the beginning of the end of the old AMBS! It is why Joe Rubenfeld said "we're there." This data expected any day now will be used to improve the accuracy of the "validation data" ICON gets in it's lab, preceding commercialization in December.
The old AMBS was always short on money, but not for long. This data will just about put the nail in that coffin, because it means LymPro revenue will be starting in 4 months! Wall Street responds to revenue. It is green, it is verifiable, and it is spectacular!
This data increases the level of certainty AMBS will not only survive but will thrive! That will bring in bigger and bigger investors who will drive up the pps in the coming weeks.
The old AMBS was always short on money, but not for long. This data will just about put the nail in that coffin, because it means LymPro revenue will be starting in 4 months! Wall Street responds to revenue. It is green, it is verifiable, and it is spectacular!
This data increases the level of certainty AMBS will not only survive but will thrive! That will bring in bigger and bigger investors who will drive up the pps in the coming weeks.
(0)
(0)
